TITLE

Relationship Between Vascular Endothelial Growth Factor and Nuclear Factor-?B in Renal Cell Tumors

PUB. DATE
October 2008
SOURCE
Croatian Medical Journal;2008, Vol. 49 Issue 5, p608
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
35116117

 

Related Articles

  • Novel Treatments.  // Current Medical Literature: Kidney Cancer;Sep2009, Vol. 1 Issue 3, p90 

    The article presents a study on the efficiency of the new drugs for the treatment of renal cell carcinoma (RCC) in the U.S. A trial has been conducted to be able to investigate the relationship between the epidermal growth factor receptor (EGFR) pathway and the vascular endothelial growth factor...

  • Do kidney tubules serve an angiogenic soup? Woolf, Adrian S. // Kidney International;Aug2004, Vol. 66 Issue 2, p862 

    Editorial. Investigates whether renal tubules express vascular endothelial growth factor (VEGF). Functional relationship between tubular VEGF-A and the state of the adjacent renal cortical microcirculation; Factors that modulate the expression of VEGF-A by renal tubules; Complexity of tumor...

  • An overview of angiogenesis and renal cell carcinoma. De, Shankhajit; Dey, Yadu Nandan; Sarkar, Piyali; Gaidhani, Sudesh // International Journal of Nutrition, Pharmacology, Neurological D;Jan2012, Vol. 2 Issue 1, p3 

    Renal cell carcinoma (RCC) is the most common malignant tumor of the kidney, and the incidence is increasing very rapidly across all population groups. Accumulation of hypoxia-induced factors and the over-expression of vascular endothelial growth factor (VEGF) are the most important predisposing...

  • Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology. Keyes, Kristan A.; Mann, Larry; Cox, Karen; Treadway, Patti; Iversen, Philip; Chen, Yun-Fei; Teicher, Beverly A. // Cancer Chemotherapy & Pharmacology;Apr2003, Vol. 51 Issue 4, p321 

    Tumor angiogenesis is essential for tumor growth and metastasis formation. Luminex methodology was used to measure the levels of four angiogenic cytokines in cell culture medium and in the plasma of mice bearing human tumors. We obtained plasma and conditioned culture medium from 12 different...

  • Thalidomide promising in treatment of metastatic RCC. Goodman, Alice // Urology Times;Mar2000, Vol. 28 Issue 3, p1 

    Focuses on the potential of thalidomide in treating metastatic renal cell carcinoma (RCC) but not in patients with other solid tumor types. Anti-angiogenic mechanism of thalidomide; Destabilization in the messages of tumor necrosis factor-alpha, interleukin-6 and vascular endothelial growth...

  • ESMO special symposium: renal cell cancer: a look to the future.  // Annals of Oncology;Sep2008 Supplement 8, Vol. 19, p24 

    The article presents abstracts on renal cell cancer which include vascular endothelial growth factor biology and resistance, mTOR pathway inhibition in renal cell cancer, and future problems related to renal cell cancer.

  • Closing in on treatments for KIDNEY CANCER. Pfeiffer, Naomi // Drug Topics;5/22/2006, Vol. 150 Issue 10, p24 

    The article reports on the approval of the drugs sunitinib and sorafenib as treatment for renal cell carcinoma by the U.S. Food and Drug Administration (FDA). The drugs are indicated for tumor cell growth and angiogenesis inhibitors that target the multiple receptors for the tyrosine kinases....

  • A HEART-MENDING TALE. Morrow, Claire // Investigate;Sep2005, Vol. 5 Issue 56, p82 

    Provides information on various treatments for heart disease. Coronary artery bypass graft; Angiogenesis; Vascular endothelial growth factor B.

  • Renal cell cancer: is immunotherapy dead? Wagstaff, J // Annals of Oncology;Sep2007 Supplement 9, Vol. 18, pix94 

    The article discusses the role of immunotherapy in renal cell cancer management. It explains the use of interleukin-2 and interferon as immunotheraoy agents for patients with metastatic renal cell cancer. The therapeutic effects of allogenic bone marrow and stem cell transplantation on patients...

  • Platelet-derived growth factor-A and vascular endothelial growth factor-C contribute to the development of pulmonary tumor thrombotic microangiopathy in gastric cancer. Abe, Hiroyuki; Hino, Rumi; Fukayama, Masashi // Virchows Archiv;May2013, Vol. 462 Issue 5, p523 

    Pulmonary tumor thrombotic microangiopathy is a rare but lethal complication in cancer-bearing patients, particularly those with gastric cancer. It is characterized by cancer cell emboli with marked intimal proliferation. In the present study, we tried to elucidate the pathogenesis of pulmonary...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics